FDA Grants AP Status for Diltiazem Hydrochloride ANDA216327
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Diltiazem Hydrochloride submitted by Sciegen Pharmaceuticals.
Company
Pharmaceutical intelligence for Sciegen Pharmaceuticals with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.